Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Paweł Kamil Serafin has a total of 30 co-authors. Here are the top co-authors by number of shared publications:

  • Patrycja Koszałka

    Laboratory of Cell Biology and Immunology, Instituteof Medical Biotechnology and Experimental Oncology, Intercollegiate Faculty of Biotechnologyof the University of Gdansk and Medical University of Gdansk, Medical University of Gdansk, Gdansk, Poland

    2 shared publications
  • A. Michno

    Department of Clinical Biochemistry Medical University of Gdańsk Gdańsk Poland

    1 shared publication
  • A. Mielewczyk‐Gryń

    Department of Solid State Physics, Faculty of Applied Physics and Mathematics Gdańsk University of Technology Gdańsk Poland

    1 shared publication
  • A. Pałubicka

    Department of Laboratory Diagnostics and Microbiology with Blood Bank, Specialist Hospital in Kościerzyna Kościerzyna Poland

    1 shared publication
  • Adriana Mika

    Department of Pharmaceutical Biochemistry, Medical University of Gdańsk, Poland

    1 shared publication
  • Agata Zwara

    Department of Pharmaceutical Biochemistry, Medical University of Gdańsk, Poland

    1 shared publication

Latest Publications

  • Open Access

    Chitosan‐Nanogold and Chitosan‐Nanozinc Electrodeposited Coatings for Biomedical Applications

    by M. Bartmański, M. Wekwejt, K. Urbanowicz, A. Mielewczyk‐Gryń, G. Gajowiec, A. Pałubicka, A. Michno, P. K. Serafin, P. Koszałka

    Bacterial infections represent a significant challenge to the success rate of both short‐ and long‐term titanium implants. Consequently, there is a persistent need for effective strategies to prevent such infections. In this study, chitosan‐based coatings modified with gold or zinc nanoparticles, recognized for their antibacterial properties, were electrophoretically deposited (EPD) onto the Ti13Zr13Nb alloy and thoroughly characterized. The effects of EPD voltage, surfactant use, and metallic nanoparticle type and concentration were investigated with regard to the microstructure and properties of the obtained chitosan‐based coatings. Incorporating metallic nanoparticles into the chitosan matrix increased surface roughness (from 54 nm to even 146 nm), particularly at higher EPD voltages, resulting in a composite structure containing nanometal clusters. The addition of gold nanoparticles reduced the thickness of the coatings (from 3.90 μm for the chitosan coating with Tween20–3.43 μm); zinc had no effect. Reducing the deposition voltage from 20 V to 10 V resulted in a thickness reduction of around 50% for all tested modifications. The improvement in plastic deformation resistance (indicated by the H3/E2 ratio) was demonstrated for gold and zinc coatings deposited at lower voltages (from 0.34 MPa for the chitosan coating with Tween20 to 1.00 MPa for the gold half and 1.78 MPa for the zinc coating). A twofold increase in voltage resulted in a significant enhancement of coating adhesion—by approximately 177% for gold‐added coatings and 138% for zinc‐added coatings. Biological responses were dependent upon the types and concentrations of nanometals. Nanogold induced erythrocyte hemolysis, whereas nanozinc exhibited no adverse effects. Notably, gold‐doped coatings demonstrated antibacterial efficacy against Staphylococcus aureus, while zinc‐doped counterparts did not. Both nanometals, however, demonstrated reduced cytocompatibility at higher concentrations. Biological response tests indicated that 2‐fold and 4‐fold dilutions of the extracted medium do not show cytotoxicity for gold and zinc nanoparticles, respectively. These findings highlight the considerable extent to which coating parameters can be modified by adjusting selected EPD process parameters.


  • Open Access

    Knock-out of CD73 delays the onset of HR-negative breast cancer by reprogramming lipid metabolism and is associated with increased tumor mutational burden

    by Paweł Kamil Serafin, Marta Popęda, Kamila Bulak, Agata Zwara, Barbara Galikowska-Bogut, Anna Przychodzka, Adriana Mika, Tomasz Śledziński, Marcin Stanisławowski, Kamila Jendernalik, et al.


  • Open Access

    4-Pyridone-3-carboxamide-1-β-D-ribonucleoside (4PYR)—A Novel Oncometabolite Modulating Cancer-Endothelial Interactions in Breast Cancer Metastasis

    by Patrycja Koszalka, Barbara Kutryb-Zajac, Paulina Mierzejewska, Marta Tomczyk, Joanna Wietrzyk, Pawel K. Serafin, Ryszard T. Smolenski, Ewa M. Slominska

    The accumulation of specific metabolic intermediates is known to promote cancer progression. We analyzed the role of 4-pyridone-3-carboxamide-1-β-D-ribonucleoside (4PYR), a nucleotide metabolite that accumulates in the blood of cancer patients, using the 4T1 murine in vivo breast cancer model, and cultured cancer (4T1) and endothelial cells (ECs) for in vitro studies. In vivo studies demonstrated that 4PYR facilitated lung metastasis without affecting primary tumor growth. In vitro studies demonstrated that 4PYR affected extracellular adenine nucleotide metabolism and the intracellular energy status in ECs, shifting catabolite patterns toward the accumulation of extracellular inosine, and leading to the increased permeability of lung ECs. These changes prevailed over the direct effect of 4PYR on 4T1 cells that reduced their invasive potential through 4PYR-induced modulation of the CD73-adenosine axis. We conclude that 4PYR is an oncometabolite that affects later stages of the metastatic cascade by acting specifically through the regulation of EC permeability and metabolic controls of inflammation.